Biotest AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biotest AG with three other
pharmaceutical manufacturers in Europe:
Recipharm AB (publ)
sales of 4.68 billion Swedish Kronor [US$555.59 million]
of which 43%
(614.49 million Euro [US$721.23 million]
of which 51%
was Non-Proprietary Homeopathic Medicines), and
based in the United Kingdom
(£447.50 million [US$595.87 million]
of which 37%
During the year ended December of 2016, sales at
Biotest AG were 553.10 million Euro (US$649.18 million).
decrease of 6.2%
versus 2015, when the company's sales were 589.60 million Euro.
Contributing to the drop in overall sales was the 17.6% decline
in Other, from 8.50 million Euro to 7.00 million Euro.
There were also decreases in sales in
Therapy (down 15.7% to 346.80 million Euro)
However, these declines were partially offset by the increase in sales of
Plasma and Services (up 17.4% to 199.30 million Euro)